BioMark Diagnostics Inc.
BUX
CNSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.68% | -1.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.68% | -1.09% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 3.68% | -1.09% | |||
| SG&A Expenses | -22.49% | 61.30% | |||
| Depreciation & Amortization | -54.08% | 278.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.09% | 87.08% | |||
| Operating Income | 35.48% | -98.58% | |||
| Income Before Tax | -2.28% | -22.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.28% | -22.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.28% | -22.91% | |||
| EBIT | 35.48% | -98.58% | |||
| EBITDA | 35.75% | -100.19% | |||
| EPS Basic | -3.57% | -833.33% | |||
| Normalized Basic EPS | -5.88% | -750.00% | |||
| EPS Diluted | -3.57% | -833.33% | |||
| Normalized Diluted EPS | -5.88% | -750.00% | |||
| Average Basic Shares Outstanding | 0.00% | -88.13% | |||
| Average Diluted Shares Outstanding | 0.00% | -88.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||